Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite - Stable Colorectal Carcinoma

Trial Profile

A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite - Stable Colorectal Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs CXD 101 (Primary) ; Nivolumab (Primary)
  • Indications Carcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CAROSELL
  • Sponsors Celleron Therapeutics
  • Most Recent Events

    • 07 Feb 2019 According to the Cancer Research UK Trial Registry record, Professor Rachel Kerr is the chief investigator of this study.
    • 07 Feb 2019 According to the Cancer Research UK Trial Registry record, the expected recruitment end date for this trial is 22nd May 2019.
    • 14 Jan 2019 According to a Celleron Therapeutics media release, a total of nine (n=9) volunteers have now been treated and followed for at least one month. Results have been reviewed by the study Data and Safety Monitoring Committee and recommended doses and progression into a Phase II efficacy assessment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top